| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Norio Yasui-Furukori, Tsuyoshi Kondo, Akihito Suzuki, Kazuo Mihara, Sunao Kanek. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology. vol 162. issue 1. 2003-01-02. PMID:12107619. |
comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. |
2003-01-02 |
2023-08-12 |
human |
| Paul B Fitzgerald, Timothy L Brown, Z Jeff Daskalakis, J Kulkarn. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology. vol 162. issue 1. 2003-01-02. PMID:12107621. |
a transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. |
2003-01-02 |
2023-08-12 |
Not clear |
| A Broerse, T J Crawford, J A den Boe. Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study. The Journal of neuropsychiatry and clinical neurosciences. vol 14. issue 4. 2002-12-26. PMID:12426415. |
differential effects of olanzapine and risperidone on cognition in schizophrenia? |
2002-12-26 |
2023-08-12 |
human |
| John M Davis, Nancy Che. Clinical profile of an atypical antipsychotic: risperidone. Schizophrenia bulletin. vol 28. issue 1. 2002-12-19. PMID:12047021. |
moreover, risperidone was more effective than haloperidol on symptoms nonresponsive and responsive to haloperidol; its effects on negative symptoms were independent of its effects on extrapyramidal symptoms; and it was effective in treating depression in schizophrenia. |
2002-12-19 |
2023-08-12 |
Not clear |
| Haluk A Savas, Bunyami Unal, Hulya Erbagci, Serap Inaloz, Hasan Herken, Sinan Canan, Erdem Gumusburun, S Salih Zorogl. Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. Neuropsychobiology. vol 46. issue 2. 2002-11-25. PMID:12378121. |
hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. |
2002-11-25 |
2023-08-12 |
human |
| Haluk A Savas, Bunyami Unal, Hulya Erbagci, Serap Inaloz, Hasan Herken, Sinan Canan, Erdem Gumusburun, S Salih Zorogl. Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. Neuropsychobiology. vol 46. issue 2. 2002-11-25. PMID:12378121. |
the purpose of this study was to assess the significance of the hippocampal volume differences and its relation with risperidone treatment in schizophrenia. |
2002-11-25 |
2023-08-12 |
human |
| Alina Borkowska, Aleksander Araszkiewicz, Andrezej Rajewski, Janusz K Rybakowsk. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. Neuropsychobiology. vol 46. issue 2. 2002-11-25. PMID:12378125. |
risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. |
2002-11-25 |
2023-08-12 |
Not clear |
| J Peuskens, H J Möller, A Puec. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 12. issue 4. 2002-11-15. PMID:12126869. |
amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. |
2002-11-15 |
2023-08-12 |
Not clear |
| J Peuskens, H J Möller, A Puec. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 12. issue 4. 2002-11-15. PMID:12126869. |
the brief psychiatric rating scale (bprs) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia. |
2002-11-15 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Jeffrey A Lieberman, Leslie Citrome, Brian Sheitman, Miranda Chakos, Joseph P McEvo. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. The Journal of clinical psychiatry. vol 63. issue 10. 2002-11-15. PMID:12416603. |
we present an open-label prospective 14-week trial with olanzapine in patients with schizophrenia and schizoaffective disorder whose treatment resistance to clozapine, olanzapine, risperidone, and haloperidol had been determined prospectively. |
2002-11-15 |
2023-08-12 |
Not clear |
| L Hosák, R Bahbou. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. European psychiatry : the journal of the Association of European Psychiatrists. vol 17. issue 4. 2002-11-07. PMID:12231267. |
costs and outcomes of risperidone treatment in schizophrenia in the czech republic. |
2002-11-07 |
2023-08-12 |
Not clear |
| L Hosák, R Bahbou. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. European psychiatry : the journal of the Association of European Psychiatrists. vol 17. issue 4. 2002-11-07. PMID:12231267. |
the aim of the study was to compare the costs and outcomes of using risperidone versus classical neuroleptics in treatment of schizophrenia in order to see if there was any cost advantage in restricting use of more recent antipsychotics. |
2002-11-07 |
2023-08-12 |
Not clear |
| L Hosák, R Bahbou. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. European psychiatry : the journal of the Association of European Psychiatrists. vol 17. issue 4. 2002-11-07. PMID:12231267. |
= 9.74) suffering from schizophrenia or schizoaffective disorder were treated with risperidone while 67 patients (39 women) with the same diagnoses with a mean age of 35.7 years (s.d. |
2002-11-07 |
2023-08-12 |
Not clear |
| David A Smelson, Miklos F Losonczy, Craig W Davis, Maureen Kaune, John Williams, Douglas Ziedoni. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 47. issue 7. 2002-10-29. PMID:12355680. |
risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. |
2002-10-29 |
2023-08-12 |
Not clear |
| Matthew A Fuller, Kenneth M Shermock, Michelle Secic, Jonathan S Laich, Michael B Durki. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatric services (Washington, D.C.). vol 53. issue 7. 2002-10-18. PMID:12096169. |
service use and costs among va patients with schizophrenia taking risperidone or olanzapine. |
2002-10-18 |
2023-08-12 |
Not clear |
| Matthew A Fuller, Kenneth M Shermock, Michelle Secic, Jonathan S Laich, Michael B Durki. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatric services (Washington, D.C.). vol 53. issue 7. 2002-10-18. PMID:12096169. |
the authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine. |
2002-10-18 |
2023-08-12 |
Not clear |
| Carla M Canuso, Jill M Goldstein, Joanne Wojcik, Ree Dawson, Danielle Brandman, Anne Klibanski, Joseph J Schildkraut, Alan I Gree. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry research. vol 111. issue 1. 2002-10-10. PMID:12140115. |
sixteen premenopausal women with schizophrenia and schizoaffective disorder, eight treated with an antipsychotic with prolactin-elevating potential (five with typical antipsychotics and three with risperidone) and eight treated with an antipsychotic with prolactin-sparing potential (seven with olanzapine and one with clozapine), were studied for eight weeks. |
2002-10-10 |
2023-08-12 |
human |
| E S Drozdo. [Rispolept (risperidone) efficacy in the treatment of patients with schizophrenia and psychoactive drug dependence]. Voenno-meditsinskii zhurnal. vol 323. issue 7. 2002-10-10. PMID:12192989. |
[rispolept (risperidone) efficacy in the treatment of patients with schizophrenia and psychoactive drug dependence]. |
2002-10-10 |
2023-08-12 |
Not clear |
| Howard C Margolese, Guy Chouinard, Linda Beauclair, Marie-Claire Bélange. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. Journal of clinical psychopharmacology. vol 22. issue 4. 2002-09-18. PMID:12172332. |
a 3-year open-label study was conducted to determine the long-term safety and efficacy of quetiapine monotherapy in schizophrenia and schizoaffective disorder.twenty-three male outpatients previously stable but with inter-episode residual symptoms on classical antipsychotics and/or risperidone and who had complained of side effects were selected. |
2002-09-18 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Yue-Cune Chang, Chi-Chiang Chiu, Tzu-Ting Chen, Sue-Hong Lee, Wen-Ho Chan. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. Journal of clinical psychopharmacology. vol 22. issue 4. 2002-09-18. PMID:12172333. |
influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. |
2002-09-18 |
2023-08-12 |
Not clear |